TSBX Turnstone Biologics Corp.

Nasdaq turnstonebio.com


$ 0.36 $ 0.01 (1.43 %)    

Friday, 08-Aug-2025 15:59:01 EDT
QQQ $ 605.09 $ -5.78 (-0.95 %)
DIA $ 465.96 $ -3.24 (-0.69 %)
SPY $ 667.72 $ -4.20 (-0.63 %)
TLT $ 92.06 $ 0.07 (0.08 %)
GLD $ 377.34 $ 4.47 (1.2 %)
$ 0.355
$ 0.35
$ 0.00 x 0
$ 0.00 x 0
-- - --
$ 0.29 - $ 2.42
283,774
na
8.21M
$ 2.02
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-29-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-14-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-10-2023 09-30-2023 10-Q
9 09-01-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 xoma-royalty-to-acquire-turnstone-biologics-for-034-per-share-plus-cvr-in-august-targeted-merger-deal

Pursuant and subject to the terms of the Merger Agreement, XOMA Royalty will commence a tender offer (the "Offer") by J...

 turnstone-biologics-q1-eps-051-misses-026-estimate

Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of...

 reported-friday-turnstone-biologics-q4-2024-gaap-eps-056-beats-069-estimate-cash-289m

Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $...

 turnstone-biologics-q3-eps-074-beats-086-estimate

Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $...

 b-of-a-securities-downgrades-turnstone-biologics-to-neutral-lowers-price-target-to-05

B of A Securities analyst Charlie Yang downgrades Turnstone Biologics (NASDAQ:TSBX) from Buy to Neutral and lowers the price...

 turnstone-biologics-expects-streamlining-of-operations-to-extend-cash-runway-into-q2-of-2026-realigns-resources-to-focus-on-clinical-advancement-of-selected-tumor-infiltrating-lymphocyte-therapy

The Company will direct resources towards advancing the development of its clinical program, TIDAL-01, over other preclinical p...

 b-of-a-securities-maintains-buy-on-turnstone-biologics-lowers-price-target-to-10

B of A Securities analyst Geoff Meacham maintains Turnstone Biologics (NASDAQ:TSBX) with a Buy and lowers the price target f...

 piper-sandler-maintains-overweight-on-turnstone-biologics-lowers-price-target-to-375

Piper Sandler analyst Joseph Catanzaro maintains Turnstone Biologics (NASDAQ:TSBX) with a Overweight and lowers the price ta...

 turnstone-biologics-shifts-focus-to-high-unmet-medical-need-cancers-shares-initial-data-from-colorectal-cancer-cell-therapy-study

Turnstone Biologics stock drops after Phase 1 STARLING trial data reveals mixed results for TIDAL-01 in metastatic colorectal c...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION